Compared to plasma, bronchial washing fluid shows higher diagnostic yields for detecting EGFR-TKI sensitizing mutations by ddPCR in lung cancer.

Respiratory Research
Sang Hoon LeeYoon Soo Chang

Abstract

The rate of diagnosis of advanced lung adenocarcinoma must be improved. In this study, we compared the detection rates of EGFR-tyrosine kinase inhibitor-sensitizing mutations (mEGFRs) in bronchial washing fluid (BWF) and the plasma of patients with lung adenocarcinoma using the tissue genotype as the standard reference. Paired blood and BWF specimens were collected from 73 patients with lung cancer. The tumor EGFR mutation status was determined by genotyping of the plasma and BWF samples using droplet digital PCR (ddPCR). The study cohort included 26, 10, 10, and 27 patients with stage I, II, III, and IV disease. Of the 73 cases, 35 had a wild-type EGFR, and 19 had the L858R substitution and exon 19 deletion mutations. The areas under the receiver operator characteristic curves for sensitivity vs. specificity of ddPCR were 0.895 [95% confidence interval (CI): 0.822-0.969] for BWF and 0.686 (95% CI: 0.592-0.780) for plasma (p < 0.001). The fractional abundance was higher in BWF of the mEGFR-positive cases than in the plasma (p = 0.004), facilitating easy threshold setting and discrimination between mEGFR-positive and negative cases. When genotyping results obtained using plasma and BWF were compared for early lung cancer (stages...Continue Reading

References

Jan 1, 1992·Respiration; International Review of Thoracic Diseases·G Semenzato, V Poletti
Nov 3, 2007·Seminars in Respiratory and Critical Care Medicine·Venerino PolettiMarco Chilosi
Aug 21, 2009·The New England Journal of Medicine·Tony S MokMasahiro Fukuoka
Feb 22, 2011·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Tonio OumeraciNils von Neuhoff
Feb 28, 2013·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Alda L TamSanjay Gupta
Jan 23, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Luis A Diaz, Alberto Bardelli
Oct 24, 2015·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Kenneth S ThressJ Carl Barrett
Feb 9, 2017·Scientific Reports·Ana Sofia CarvalhoRune Matthiesen
Feb 15, 2017·Clinical Chemistry and Laboratory Medicine : CCLM·Sojung ParkChang-Min Choi
Dec 8, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A K KrugJ Skog
Jan 10, 2018·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal
May 22, 2018·Journal of Thoracic Disease·Wenhua LiangJianxing He
Jun 19, 2018·Current Oncology·M Cabanero, M S Tsao
Jul 28, 2018·Translational Lung Cancer Research·Patricia M de GrootReginald F Munden
Mar 21, 2019·Frontiers in Oncology·Jatta SaarenheimoAntti Jekunen

❮ Previous
Next ❯

Citations

Aug 28, 2021·Biomedicines·Irina Palacín-AlianaÁngel Ayuso-Sacido
Nov 14, 2021·Molecular Diagnosis & Therapy·Susana Olmedillas-LópezDamián García-Olmo

❮ Previous
Next ❯

Methods Mentioned

BETA
by surgical resection
biopsy
biopsies
bronchoalveolar
PCR
chip
genotyping
sedation

Software Mentioned

PANAMutyper
gmodels R
R
pROC
SPSS
QuantaSoft

Related Concepts

Related Feeds

CFTR Mutant Structural Therapy

Over 1700 different mutations in the CFTR genes have been shown to cause cystic fibrosis. Here is the latest research on structural therapy for CFTR mutants.